For instance, MUC1, which is expressed in over 90% of BC and 95% of TNBC cases, has been targeted using MUC28z‐CAR T cells that recognize aberrantly glycosylated MUC1, leading to antigen‐specific cytotoxicity and significant tumor reduction in xenograft models [614]. This evidence concerns the gene MUC1 and neoplasm.